Clovis Oncology, Inc.

OTCPK:CLVS.Q Aktierapport

Börsvärde: US$2.2m

Clovis Oncology Tidigare resultatutveckling

Tidigare kriterier kontrolleras 0/6

Clovis Oncology har ökat intäkterna med en genomsnittlig årlig takt på 5.6%, medan Biotechs -branschen såg intäkterna växande på 33.8% årligen. Intäkterna har varit växande med en genomsnittlig takt på 16.8% per år.

Viktig information

5.59%

Tillväxttakt i vinsten

24.50%

Tillväxttakt för EPS

Biotechs Tillväxt i branschen17.04%
Intäkternas tillväxttakt16.79%
Avkastning på eget kapitaln/a
Nettomarginal-189.37%
Senaste uppdateringen av resultatet30 Sep 2022

Senaste uppdateringar av tidigare prestationer

Recent updates

Seeking Alpha • Sep 21

Clovis Oncology rises on clinical supply agreement with Isotopia

Clovis Oncology (NASDAQ:CLVS) said on Wednesday it had signed a clinical supply agreement that would provide it with Isotopia’s lutetium-177 n.c.a. for use in the development of FAP-2286, fibroblast activation protein, that targets therapeutic candidate. (CLVS) has risen 4.5% before the bell. FAP-2286 is currently being developed in the Phase 1/2 study to treat patients with advanced solid tumors. The agreement covers an initial period of two years. "Over the past four years, Isotopia has strengthened its supply chain to support the growing global demand and need for higher supply security," said Keren Moshkoviz, Deputy CEO and BD at Isotopia. FAP is highly expressed by cancer-associated fibroblasts (CAFs) which are found in the majority of cancer types, but with limited expression in healthy fibroblasts, potentially making it a suitable target across a wide range of tumors.
Seeking Alpha • Sep 12

Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

Clovis Oncology (NASDAQ:CLVS) said Rubraca as initial maintenance therapy improved progression-free survival (PFS), compared to placebo across disease risk subgroups in patients with ovarian cancer. The company presented data from a subgroup analysis of a monotherapy comparison in the phase 3 trial called ATHENA at the European Society of Medical Oncology (ESMO) Congress 2022 in Paris. ATHENA-MONO enrolled 538 women with high-grade ovarian, fallopian tube or primary peritoneal cancer. Patients who received Rubraca as maintenance therapy showed PFS (length of time during/after therapy a patient lives with the disease without it getting worse) benefit regardless of surgical outcome, whether there was complete resection during cytoreductive surgery or not, the company said in a Sept. 11 press release. In addition, patients treated with Rubraca as maintenance therapy showed benefit among all subgroups when evaluated against response per RECIST v1.1 at any time during first-line chemotherapy. Clovis noted that in other subgroups based on baseline clinical characteristics, including FIGO stage, timing of surgery, and CA-125 levels, also showed that patients treated with Rubraca experienced a PFS benefit compared to those treated with placebo. CLVS +14.78% to $1.32 premarket Sept. 12
Seeking Alpha • Aug 11

Clovis Oncology: Needs Some Encouraging Data Quickly

Funding difficulties have definitely been priced into Clovis' share price. Clovis, though, has some interesting readouts due this year and in early 2023. If data is encouraging and new funding is announced, CLVS stock could rally sharply from present levels. Intro If we look at a long-term chart of Clovis Oncology, Inc. (CLVS) (Antin Cancer Biotech Company), we see that shares topped out in 2017 and have been making sustained lower lows ever since. Suffice it to say, a lot of shareholders have been burned by this play, and if the present bearish trend continues, shares could easily test the stock's year-to-date lows of well under $1 a share. If indeed though shares swoop down to their 2022 lows in the not too distant future, the risk/reward play would be heavily skewed to the upside because of what the company still has in its locker in our opinion. Clovis Technical Chart (Stockcharts.com) Clovis Needs Capital Suffice it to say, it then would boil down to how much the company's assets are worth to a partner if indeed a third party is to enter the scene here, which now looks highly likely. Management announced on its recent quarterly earnings call that raising capital through public or private equity means is not an option at present due to the recent unsuccessful stock split. So, Clovis' current options with respect to facilitating funding seem to be to either increase the number of shares or enter into some type of licensing agreement. The reason being is that when forward-looking revenue projections and the company´s current cash-burn rate are taken into account, operations will eventually come to a grinding halt in early 2023 if no new funding is found. Rubraca Sales Are Not Growing Unfortunately, Rubraca has not performed up to expectations. This means Clovis' pipeline has literally run out of time. Rubraca sales came in at $32.1 million in the company's fiscal second quarter, which was a 6% sequential decline as well as a 13% decrease compared to the same period of 12 months prior. Covid-19 has been a clear headwind here due to fewer numbers of people going through the system. This has led to a fall-off in second-line maintenance treatment. Furthermore, recent insider selling demonstrates management's outlook on how Rubraca is expected to fare going forward, which obviously has been factored in as to when the firm will run out of money. Pipeline However, with respect to the pipeline, management was quick to point to the ongoing FAP-2286 (Lead candidate in Radionuclide therapy) LuMiere trial with respect to its recent encouraging results. When we take into account the tumor space, which is a significant area of high unmet need, along with recent evidence regarding Fap-2286's sound safety and clinical implications, this will be a trial that will be watched very closely going forward by all cohorts in this space. Then, on the Rubraca side, the ongoing TRITON3 & ATHENA studies offer the opportunity to bring to the market earlier therapy solutions for prostate and ovarian cancer patients. Regarding ovarian cancer, Clovis has plenty of indications in late stages in ATHENA-MONO & ATHENA-COMBO, where we should have updated information in this space in the latter stages of this fiscal year as well as early next year. Remember, the goal here is to widen the net so to speak with respect to patients undergoing therapy in this space. The same goes for specific prostate cancer patients in the TRITON3 trial where we should have an update over the next few months or so. Worrying Financials The question then becomes how much is this pipeline worth, notwithstanding Rubraca's U.S. and international product revenues. Remember, Clovis has well over $600 million of long-term debt on its balance sheet and continues to report negative shareholder equity. Suffice it to say, its bargaining position is not healthy, as the company will most likely have to give up more than it wishes to attract the interests of a funded third party.
Analysartikel • Aug 10

These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Today is shaping up negative for Clovis Oncology, Inc. ( NASDAQ:CLVS ) shareholders, with the analysts delivering a...
Seeking Alpha • Aug 05

Clovis Oncology Q2 2022 Earnings Preview

Clovis Oncology (NASDAQ:CLVS) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open. The consensus EPS Estimate is -$0.43 (+29.5% Y/Y) and the consensus Revenue Estimate is $37.08M (+0.7% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
Seeking Alpha • Jul 22

EMA recommends restricted use of Clovis cancer drug

The European Medicines Agency (EMA) announced on Friday Rubraca (rucaparib camsylate), a cancer medication marketed by the U.S. biotech Clovis Oncology (NASDAQ:CLVS) should no longer be used as a third line treatment for certain cancers due to concerns over safety/quality. Per the recommendation of the EMA’s Committee for Medicinal Products for Human Use (CHMP), the drug, also known as rucaparib camsylate will not be indicated as a third line option for certain patients with cancers in the ovary, fallopian tubes or peritoneum with a BRCA mutation. A review on the quality, safety and efficacy issues of the treatment led to the decision, the EMA added.  In 2018, the EU regulators granted conditional marketing authorization for Rubraca as a third line option for certain patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Previously, the oral small molecule inhibitor was authorized in Europe for certain patients in the recurrent ovarian cancer maintenance setting regardless of their BRCA mutation status.
Seeking Alpha • Jul 08

Clovis Oncology climbs 34% as shareholders reject reverse stock split

Clovis Oncology (NASDAQ:CLVS), a biotech focused anti-cancer agents, added more than 34% to reach the highest level since April after the company’s shareholders rejected a proposal to implement a reverse stock split. Disclosing the outcome of its 2022 stockholder meeting, Clovis (CLVS) said that the shareholders did not approve two proposals: the 1-for-7 reverse stock split and a concurrent plan to decrease the number of authorized shares of common stock. The company had previously adjourned its annual meeting to discuss three proposals. However, shareholders have greenlighted only one proposal related to a stock incentive plan when the meeting was resumed yesterday.   Despite more than a threefold rise over the past 30 days, Clovis (CLVS) shares remain ~45% lower than the year-ago level, as shown in this graph.
Seeking Alpha • Apr 25

Clovis: Shifting Toward Nuclear Medicine

Clovis, a "trading stock," has some shakiness in its fundamentals. Moreover, the shares tend to rise and fall for you to trade for short-term gains. Due to upcoming catalysts in June, Clovis is a trading stock that is about to embark on another bullish cycle. Despite being a trading stock, Clovis shares are still changing hands at a deep valuation to their true value.
Seeking Alpha • Mar 31

Clovis Oncology: Forging A Fresh Perspective

Clovis Oncology recently reported impressive data from their ATHENA-MONO Phase III study. The ATHENA-MONO data should support the use of Rubraca in the first-line ovarian setting. The company is scheduled to report data from two more Phase III studies for Rubraca this year. Clovis has a chance to be a leader in targeted radionuclide therapies. FAP-2286 is the company's lead FAP program and will be the first TRT to enter the clinic. It is time to take on a fresh perspective. The company’s recent earnings report and company updates hold key materials required to forge a new thesis for CLVS. CLVS is now trading up on the ATHENA-MONO news and is starting to break long-term downtrends on both the Monthly and Daily charts.
Analysartikel • Feb 24

News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

One thing we could say about the analysts on Clovis Oncology, Inc. ( NASDAQ:CLVS ) - they aren't optimistic, having...
Seeking Alpha • Jan 11

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

The stock is significantly undervalued and this year could unlock significant near-term value in the form of ATHENA trial data. Long-term (3-4 years) first price target = $40 (15x potential). Blue sky (5 years) price target = $88 (32x potential). The article provides the target markets and calculations behind the price targets.
Seeking Alpha • Dec 30

Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward

Clovis Oncology has had a rough 2021, with Rubraca sales continuing to disappoint. The company’s Q3 sales revealed a slight increase quarter-over-quarter and a slight decrease year-over-year. The company points to COVID-19 headwinds and a decrease in the number of new ovarian cancer diagnoses. I am leaning more towards the lackluster demand for PARP inhibitors. The company is promoting their FAP efforts, which can keep CLVS in play in the coming years. Targeted radionuclide therapies could reignite the CLVS buyout chatter. 2022 could be a pivotal year for Clovis and its share price. The company has several potent milestones that could provide opportunities to manage a position. The prolonged sell-off has knocked the premium right out of CLVS. I believe the ticker is now discounted and offers a great risk-reward for speculative investment.
Seeking Alpha • Oct 07

Clovis Oncology Stock: Only Glimmers Of Hope

Today, we revisit Clovis Oncology for the first time in many years. The company has destroyed tons of shareholder value in that time as the PARP inhibitor space has been very disappointing to date. Can the company and stock rebound? We attempt to answer that question in the investment analysis below.
Seeking Alpha • Jul 30

Clovis: Compelling With Upcoming Catalysts

After a 25% selloff in the last 6 weeks, Clovis presents a compelling risk/reward ratio with upcoming catalysts in the next 3 months. Athena data is due in September which could move Rubraca into the largest oncology market in its class and make it a potential blockbuster. Targeted radiotherapy is the future of cancer treatment and Clovis is a pioneer in this area with its FAP pipeline. Earnings on August 4 will provide much-needed clarity from management.
Analysartikel • Jun 17

Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Shareholders of Clovis Oncology, Inc. ( NASDAQ:CLVS ) will have been dismayed by the negative share price return over...
Analysartikel • Mar 17

Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

Investors may wish to note that an insider of Clovis Oncology, Inc. , Thomas Harding, recently netted US$56k from...
Analysartikel • Feb 22

How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

It is doubtless a positive to see that the Clovis Oncology, Inc. ( NASDAQ:CLVS ) share price has gained some 59% in the...
Analysartikel • Dec 31

What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Every investor in Clovis Oncology, Inc. ( NASDAQ:CLVS ) should be aware of the most powerful shareholder groups. Large...

Fördelning av intäkter och kostnader

Hur Clovis Oncology tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.

Resultat- och intäktshistorik

OTCPK:CLVS.Q Intäkter, kostnader och resultat (USD Millions )
DatumIntäkterIntäkterG+A KostnaderFoU-kostnader
30 Sep 22133-252126151
30 Jun 22140-263127167
31 Mar 22145-258128176
31 Dec 21149-265128187
30 Sep 21156-299136201
30 Jun 21157-310142218
31 Mar 21160-336151242
31 Dec 20165-369164258
30 Sep 20161-370168273
30 Jun 20159-385171288
31 Mar 20152-413178289
31 Dec 19143-400183283
30 Sep 19134-400187282
30 Jun 19119-396187268
31 Mar 19110-377184250
31 Dec 1895-368176231
30 Sep 1882-321165198
30 Jun 1876-291158173
31 Mar 1867-366149154
31 Dec 1756-346139142
30 Sep 1739-365113159
30 Jun 1722-37087174
31 Mar 177-32460209
31 Dec 160-34941251
30 Sep 160-39837273
30 Jun 160-43136294
31 Mar 160-37334287
31 Dec 150-35331269
30 Sep 150-28828243
30 Jun 150-22925202
31 Mar 150-19223170
31 Dec 1414-16021138
30 Sep 1414-13419110
30 Jun 1414-1151891
31 Mar 1414-1001679
31 Dec 130-851767
30 Sep 130-761461
30 Jun 130-741260
31 Mar 130-711157
31 Dec 120-741158

Kvalitetsintäkter: CLVS.Q är för närvarande olönsam.

Växande vinstmarginal: CLVS.Q är för närvarande olönsam.

Fritt kassaflöde vs resultatanalys

Analys av tidigare vinsttillväxt

Resultatutveckling: CLVS.Q är olönsam, men har minskat förlusterna under de senaste 5 åren med en hastighet av 5.6% per år.

Accelererande tillväxt: Det går inte att jämföra CLVS.Q s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt

Resultat vs industri: CLVS.Q är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Biotechs branschen ( 43% ).

Avkastning på eget kapital

Hög ROE: CLVS.Q s skulder överstiger dess tillgångar, så det är svårt att beräkna dess avkastning på eget kapital.

Avkastning på tillgångar

Avkastning på sysselsatt kapital

Upptäck starka bolag som tidigare presterat bra

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2023/07/12 21:47
Aktiekurs vid dagens slut2023/07/10 00:00
Intäkter2022/09/30
Årlig intjäning2021/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Clovis Oncology, Inc. bevakas av 16 analytiker. av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Tazeen AhmadBofA Global Research
Debjit ChattopadhyayBrean Capital Historical (Janney Montgomery)
Douglas BuchananBrean Capital Historical (Janney Montgomery)